Similar articles

• Increased levels of spliced RNA account for augmented expression from the MFG retroviral vector in hematopoietic cells.

  Krall WJ, Skelton DC, Yu XJ, Riviere I, Lehn P, Mulligan RC, Kohn DB. Krall WJ, et al. Gene Ther. 1996 Jan;3(1):37-48. Gene Ther. 1996. PMID: 8929910
• Analysis of the relative level of gene expression from different retroviral vectors used for gene therapy.

  Byun J, Kim SH, Kim JM, Yu SS, Robbins PD, Yim J, Kim S. Byun J, et al. Gene Ther. 1996 Sep;3(9):780-8. Gene Ther. 1996. PMID: 8875226
• Retroviral vectors for use in human gene therapy for cancer, Gaucher disease, and arthritis.

  Robbins PD, Tahara H, Mueller G, Hung G, Bahnson A, Zitvogel L, Galea-Lauri J, Ohashi T, Patrene K, Boggs SS, et al. Robbins PD, et al. Ann N Y Acad Sci. 1994 May 31;716:72-88; discussion 88-9. doi: 10.1111/j.1749-6632.1994.tb21704.x. Ann N Y Acad Sci. 1994. PMID: 7912915 Review. No abstract available.
• Engineering the splice acceptor for improved gene expression and viral titer in an MLV-based retroviral vector.

  Lee JT, Yu SS, Han E, Kim S, Kim S. Lee JT, et al. Gene Ther. 2004 Jan;11(1):94-9. doi: 10.1038/sj.gt.3302138. Gene Ther. 2004. PMID: 14681702
• Technology evaluation: MFG-IRAP, University of Pittsburgh.

  Baragi VM. Baragi VM. Curr Opin Mol Ther. 2000 Apr;2(2):216-20. Curr Opin Mol Ther. 2000. PMID: 11249645 Review.